SEC Form 4 · accession 0001780649-26-000014

Adaptive Biotechnologies Corp · ADPT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Chad M Robins

Officer — CEO and Chairman · Director

Period of report

Aug 17, 2026

Accepted (ET)

Aug 19, 2026 · 8:15 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001478320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Aug 17, 2026	M	321,324	$6.55	A	2,501,842	D
Common Stock^F1	Aug 17, 2026	S	318,799	$25.08	D	2,183,043	D
Common Stock^F2	Aug 17, 2026	S	2,525	$25.57	D	2,180,518	D
Common Stock	Aug 18, 2026	M	278,676	$6.55	A	2,459,194	D
Common Stock^F3	Aug 18, 2026	S	278,472	$24.48	D	2,180,722	D
Common Stock^F4	Aug 18, 2026	S	204	$25.14	D	2,180,518	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F5	$6.55	Aug 17, 2026	M	321,324	D	—	Feb 7, 2028	Common Stock	321,324	278,676	D
Stock Option (right to buy)^F5	$6.55	Aug 18, 2026	M	278,676	D	—	Feb 7, 2028	Common Stock	278,676	0	D

Explanation of responses

F1The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 to $25.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F2The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.64, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5The option was fully vested and exercisable and would have expired on February 7, 2028.